MRK
6/20/22 MRKMerck & Company, Inc. ( NYSE:MRK )
Sector: Health Technology (Pharmaceuticals: Major)
Market Capitalization: $213.987B
Current Price: $84.62
Breakout price: $91.40
Buy Zone (Top/Bottom Range): $83.60-$79.90
Price Target: $103.20-$105.80
Estimated Duration to Target: 672-696d
Contract of Interest: $MRK 1/19/24 85c
Trade price as of publish date: $10.17/contract
MRK - Lower Volatility PeriodMRK has seen strong bullish movement in the past, right now it is in recovery phases of its last bearish move
This can be compared to an earlier phase in price development (in rectangle boxes)
Once this recovery is completed strong bullish movement should ensue, pushing price above the trend line in white
50MA is in white
MRK - Multi decade long breakout?
Monthly chart is showing nice accumulation at the ATH.
Everything seems to favor a breakout that should last a while.
Keep an open mind...these are golden set ups and offer plenty of time to enter.
Ideal entry is breakout and back-test.
Merck gaining momentum. MRKImmediate targets 85, 86. Invalidation at 76.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe
MRK impulsive move short termTarget 83-85 if we see continuation to the upside. Looking good for a short term move this week.
Merck and Co. gearing for a boost. MRKAnd that's expected to an extent after a sizeable and quick drop. Merck did one, and fractally we are due to a rise that can potentially be viable percentage wise. But who knows what will happen.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
Merck (MRK) BullishMRK bounced off resistance yesterday. It also formed On Balance Volume divergence. I am bullish on Merck stock.
MRK Analysis - Rising WedgeRising Wedge and Ascending H&S, leading to a break down over a weak uptrend line
down to the .618 Fibonacci line
Rising wedges and H&S patterns are both considered bearish
Attaching my thoughts about the ascending H&S
MERCK ANALYSISI would like to see MERCK pull back to $81-82 range. With news coming out of FDA approval of their COVID pill it will be a quick spike to the 85-95 range and then a pullback. Approval should happen the first or second week of December. Looking at options calls for $83 if stock pulls back to $81-82.
MRKWith the recent news and with everything going on, I feel like MRK is one swing that could be very beneficial. The dip was formed by a bearish flag pattern, and is followed up with news. Right now I am seeing many bullish patterns, but I'm watching for an uptrend then a small down trend to complete the bullish pennant I have in mind. I graphed the RSI with what my expectation of the graph is going to do.
20 years is a long wait, will Merck regain its glorious days ?Study this article carefully !
From a consumer perspective, if these pills are proven safe and effective with minimal side effects, I am sure the take up rate would be much higher , better still if they can be sold at pharmacies and other distribution outlets for easy access. Jabs take a longer time and the process is much longer as it requires the administration by a qualified staff from the healthcare sector. This takes time on both ends and delay the rates of vaccination to some extent.
Let's wait patiently and see which stock shows a more bullish signs in the coming weeks.
$MRK Breaking out of two year accumulation zone into new ATH's.Merck is looking primed for a run into the $90's or higher after breaking 2 years of accumulation on the weekly chart. Ideally I want to see this hold the $84 support level and then bounce back through the all time high's.
There is also huge call flow the past two days. One option chain that is getting some attention is Nov 19 $90 calls.
Morgan Stanley also raised guidance from $88 to $90 and maintained equal-weight on the stock.
Bullish.
Merck & Co: Covid news linked breakout - BullishMerck & Co., Inc. develops pharmaceutical and vaccine products. It also offers healthcare solutions and vaccines addressing animal health. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
Average Analyst Rating : Moderate Buy : Price target : $92
Hedge Fund Trend: ▼ Hedge Funds Decreased Holdings by 8.8M Shares Last Quarter.
Insider Activity : No Meaningful change last quarter
News Sentiment last week: Very Bullish
Technicals : Positive
Merck and Ridgeback Therapeutics Inc.’s experimental oral antiviral treatment is being heralded as a pill with major upside potential in the fight against the COVID-19 pandemic. Malaysia is in talks to procure an experimental antiviral pill developed by Merck & Co for COVID-19 treatment, the health minister said on Saturday.
Fundamental news brought sharp falls for the vaccine cos that have earlier made huge gains, the likes of PFEs and MRNA and others and MRK moved up sharply, breaking the range it was moving. Since its a news related move, more likely a new range would be created and previous resistance maybe difficult of breach.
Most of the stocks that had fallen because of Covid lockdowns showed glimpses of finding investor interest as Airlines, Casinos & Gamings, Crusie Liners all made substantial moves.
From a technical standpoint, its a Bollinger band blast on Daily charts. The candle formation can be tricky, but the weekly candle looks very strong Watch out for price action on Monday, dip buying should be a good strategy. I think another rotation in its way in terms of sector moves, ride this rally and watch out the Covid news regularly.
Merck&Co Analysis 05.10.2021Hello Traders,
welcome to this free and educational analysis.
I am going to explain where I think this asset is going to go over the next days/weeks and where I would look for trading opportunities.
If you have any questions or suggestions which asset I should analyse tomorrow, please leave a comment below.
I would also appreciate, if you would smash that like button and help me to create more free analysis like that.
Thank you for watching and I will see you tomorrow!
Merck is Flying based on the biased perception..!Merck data shows Molnupiravir will decrease mortality and hospitalization which is a good news, but do not forget it does not mean you do not need COVID-19 Vaccine..!
This is only for those who becomes positive for COVID test, while Vaccine is for everyone!
While many people debate about their choice of being vaccinated or not, I would like to show other countries example:
Australia:
No Jab No Pay
is an Australian policy initiative which withholds three state payments – Child Care Benefit, the Child Care Rebate and a portion of the fortnightly Family Tax Benefit part A per child – for parents of children under 20 years of age who are not fully immunized or on a recognized catch-up schedule.
No Jab No Play
is a related policy that disallows unvaccinated children from attending preschool and childcare centres, and imposes fines on childcare centres that admit unvaccinated children. The system allows exemptions for children who cannot be safely vaccinated for medical reasons.
As a doctor I respect patients choice, but when it is about public health things will become a little complicated from ethical point of view!
I got vaccinated as soon as it becomes possible, and asked all my family members to do so. I want to use this opportunity to ask you to get vaccinated and do not pay attention to misinformation.
I published short analysis on MRNA before this news:
Best,
Moshkelgosha
INO What You're Thinking...INO finally broke back above the 786 fib line. Before the last bout of selling, you'll see this level was an area of support for the former penny stock. Now, thanks to some added excitement from delta news (the variant not the airline), INO shares are popping. They also jumped back above the 786 fib. Now the question is, will it rest the 618 fib like it tried to a few weeks ago?
"Inovio Pharmaceuticals Inc. (NASDAQ: INO) has steadily climbed for the better part of the last 3 months thanks to recent pipeline progress. In June, the company had expanded its partnership with Advaccine Biopharmaceuticals Suzhou to conduct a Phase 3 segment of a trial called INNOVATE. The goal is to evaluate the safety and efficacy of the company’s INO-4800 in COVID patients. The treatment was already shown to be well tolerated and immunogenic in tested age groups in a Phase 2 study.
This month Inovio announced that it and Advaccine received a regulatory allowance for 2 heterologous prime-boost clinical trials in China using INO-4800. “VID-19. If approved, we believe INO-4800 will be well-positioned to serve the vaccine needs of the global community as both a primary and a booster vaccine due to its tolerability, balanced cross-reactive immune responses, and strong thermostability profile that does not require cold or ultra-cold-chain transport,” said Dr. J. Joseph Kim, President, and CEO of INOVIO."
Quote Source & Read more on INO: Former Penny Stocks To Watch After Merck’s ( MRK ) Latest FDA Win
BMY Flirting With Historic TerritoryWhen I say "historic" for BMY I'm not talking ATH but the stock's encroaching on an area that has been tested 3 times being rejected each time. This is the 236 fib area using 2016's high as the top anchor. It's been 5 years since BMY traded well above this area. But with the way attention is being placed on immunotherapy stocks, it could be something to keep in mind for BMY longs.
" Both Bristol-Myers and Novartis recently gave updates on new FDA updates. Novartis’ NIS793 gained FDA Orphan Drug Designation, while Bristol-Myers’ recent earnings update revealed strong sales figures from its lead cancer drug, Opdivo...B7H3 protein is a checkpoint molecule, which has very recently become a target for cancer treatment. While things are still in the very early stages for B7 molecules, as a whole, early research is also finding new potential for targeted cancer treatments. For instance, Merck’s (NYSE: MRK ) blockbuster drug, Keytruda, and Bristol-Myers’ YERVOY treatments target the same checkpoint inhibitors that are part of the B7 family (PD-1/PD-L1 and CTLA-4/CD80). They’ve also both demonstrated a clear survival benefit when it comes to immune-oncology treatment ."
Quote Source & Read More: Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio
MRK Testing the upper limits But Can It Make New Highs?MRK is back in this 382-236 fib range with both lining up pretty tightly with the current levels on the chart. 382 is a bit looser and more of a pivot area, for now, that's been a magnet for the stock over the last few weeks. Meanwhile, 236 was tested a few times and MRK was rejected each time. With the last update on Keytruda, it's going to be interesting to see what comes next.
"Merck’s (NYSE:MRK) big news on July 27th marked a watershed moment for the company’s cancer treatment, Keytruda. The Food & Drug Administration approved Keytruda for treating patients with high-risk early-stage triple-negative breast cancer (TNBC), in combination with chemotherapy. Following surgery, Keytruda could then continue as a single agent adjuvant. This approval was based on Merck’s Phase 3 KEYNOTE-522 trial....Merck’s (NYSE: MRK) blockbuster drug, Keytruda, and Bristol-Myers’ YERVOY treatments target the same checkpoint inhibitors that are part of the B7 family (PD-1/PD-L1 and CTLA-4/CD80). They’ve also both demonstrated a clear survival benefit when it comes to immune-oncology treatment...This B7H3 protein is a checkpoint molecule, which has very recently become a target for cancer treatment."
Quote Source & Read More: Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio
$MRK 3-3-3 wxy?the structure looks obvious 3-3-3 within a larger 3 wave corrective structure from Merck's ATH
MRK - Merck & Co - WEEKLY Setup - Holding the 200emaI Hate Trading Pharma But...
MRK
BUYZONE = 74 - 76
Cost Avg Down (CAD) = 72 - 70
1st Target = 79
2nd Target = 82
3rd Target = 86
HODL Target = ATH
______________________________________________________________________________________________________________________
This content is for informational, educational and entertainment purposes only. This is not in any way, shape or form financial or trading advice.
Good luck, happy trading and stay chill,
2degreez
